Background: The CPB summarizes evidence and clinical guidance across many domains. It affirms established diagnostic standards (skin testing and in‑vitro sIgE when indicated) and emphasizes that the oral food challenge (OFC) remains the diagnostic gold standard for IgE‑mediated food allergy. It also outlines settings where in‑vitro testing is preferred (e.g., patients on suppressive meds, widespread skin disease, uncooperative patients, risk of anaphylaxis) and repeats the initial in vitro screen limits of 40 inhalant / 12 food/other tests with additional testing allowed only if initial screen positive.
Evidence highlights: Sublingual immunotherapy (SLIT) has moderate evidence of efficacy for allergic rhinitis/asthma from multiple RCTs and systematic reviews (symptom and medication reductions), but heterogeneity and methodological issues remain; safety concerns include frequent local oral reactions and rare anaphylaxis reports (see SLIT systematic reviews and trials).
Oral immunotherapy (OIT) for food allergy increases desensitization rates but also substantially increases harms: the PACE meta-analysis found higher anaphylaxis risk (RR ~3.12), increased epinephrine use (RR ~2.21) and more serious adverse events; benefits versus harms are unclear.
Ara h 2 guidance: For suspected peanut allergy when a single diagnostic test is used, Ara h 2 component testing is suggested because it offers higher specificity (but lower sensitivity) compared with SPT or whole‑allergen sIgE.
Alpha‑gal (mammalian meat) evidence: Multiple observational studies support measuring alpha‑gal specific IgE in patients with delayed reactions (typically 3–6 hours after mammalian meat ingestion) presenting with urticaria/angioedema/anaphylaxis or GI symptoms with presyncope; skin tests with commercial meat extracts may be insensitive and sIgE is generally detectable.
Basophil Activation Test (BAT): Meta‑analytic data indicate BAT has relatively high specificity and good sensitivity as an adjunctive in immediate drug hypersensitivity and other settings (pooled sensitivity ~78%, specificity ~95%), but larger studies and standardization are needed and BAT is listed among tests considered experimental for routine allergy evaluation in this policy.
Depot (intramuscular) steroid risks: Observational registry data associate depot steroid injections for rhinitis with increased risk of systemic harms (e.g., diabetes RR ~1.5 and osteoporosis RR ~1.2), and guidelines recommend against routine IM depot steroids for allergic rhinitis.
Diagnostic standards and testing caveats: The policy reiterates that SPT and sIgE have good sensitivity but limited specificity; suggested literature cut‑offs exist for foods (e.g., egg and cow’s milk) but are variable and require local validation; when uncertainty persists, perform supervised OFC as the definitive diagnostic test.